Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PLAAT3 | P53816 | 2/20 | 0.50 |
| ▸ | PLAAT5 | Q96KN8 | 2/20 | 0.50 |
| ▸ | PLAAT2 | Q9NWW9 | 2/20 | 0.50 |
| ▸ | PLAAT4 | Q9UL19 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19120727 | 0.90 | MAPT (0.56) | KMT2APLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL27383420 | 0.88 | FFAR1 (0.48) | KMT2AALDH1A1MAPTFFAR1PPARG | |
| SCHEMBL3450853 | 0.85 | BCHE (0.48) | KMT2AALDH1A1MAPTFFAR1PPARG | |
| SCHEMBL1050111 | 0.84 | KMT2A (0.73) | KMT2ATDP1ALDH1A1MAPTFFAR1 | |
| SCHEMBL27744906 | 0.83 | KMT2A (0.56) | KMT2ATDP1ALDH1A1MAPTFFAR1 | |
| SCHEMBL28968066 | 0.83 | KMT2A (0.59) | KMT2ATDP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL27656774 | 0.83 | KMT2A (0.68) | KMT2ATDP1PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL10882168 | 0.82 | KMT2A (0.71) | KMT2ATDP1ALDH1A1MAPTFFAR1 | |
| SCHEMBL13978646 | 0.82 | KMT2A (0.66) | KMT2ATDP1ALDH1A1MAPTFFAR1 | |
| Hydrogen Sulfide SCHEMBL28066373 | 0.82 | KMT2A (0.71) | KMT2ATDP1ALDH1A1MAPTFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | disclosed |
| CN-101328163-A | Compounds, compositions and methods | SMITHKLINE BEECHAM CORP (US) | 2008-12-24 | — | — | CN | disclosed |
| CN-100381437-C | Compounds, compositions and methods | CYTOKINETICS INC (US) | 2008-04-16 | — | — | CN | disclosed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| CN-1662508-A | Compounds, compositions and methods | CYTOKINETICS INC (US) | 2005-08-31 | — | — | CN | disclosed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| EP-0664788-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | Byk Nederland BV (NL) | 1995-08-02 | — | — | EP | disclosed |
| WO-1994008945-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | BYK NEDERLAND BV (NL) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | KMT2A 1606/4885TDP1 562/4885PLAAT3 1270/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KMT2A 2046/4885TDP1 918/4885PLAAT3 2082/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | KMT2A 2046/4885TDP1 918/4885PLAAT3 2082/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KMT2A 2046/4885TDP1 918/4885PLAAT3 2082/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | KMT2A 2046/4885TDP1 918/4885PLAAT3 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.